With the FDA approval of Novo Nordisk’s new Wegovy weight-loss pill, the first GLP-1 drug available in oral form, production and packaging are now underway at the company’s North Carolina facilities. Footage of the packaging line, provided by Novo Nordisk, shows the end-to-end operation, from pill handling and quality checks to automated robotic case packing, highlighting the advanced technology and efficiency of the facility.
The choice of a square bottle might be a wonder, seeing that round bottles can frequently run faster than square ones on a wrapping line. Novo Nordisk did not tell us the line hurries, from the clips, the corporation is utilizing a combination of mechanical and robotic approaches to keep up with high anticipated volumes, comprising rotary operations and timing screws to maintain the square bottles moving.
While this shape might run gentler, it also has advantages: The square bottle does distinguish the product in the market and is more effective for shipping, giving it a slight sustainability division as well.
Novo Nordisk did not answer our question about anticipated volumes of the Wegovy pill for 2026, but Liz Skrbkova, senior director for Media & Stakeholder Relations at Novo Nordisk, did say, “Since launch, we have observed patients from the entire country ask for the Wegovy pill. It’s initial days, but what’s clear is that people have been waiting for Wegovy pill. There’s only one, and it’s made by Novo Nordisk, end-to-end, right here in the US.”
She says that all doses are accessible nationwide for Americans, across 70,000+ pharmacies such as Costco and CVS, the company’s own NovoCare Pharmacy, or choose telehealth benefactors and digital platforms such as WeightWatchers, Ro, LifeMD, GoodRx, and Amazon.
“Primary signs are positive, and we are fortified by feedback from our collaborators,” Skrbkova expresses. “It’s too early for us to speak about trends for Wegovy pill, but we’ll exert all our efforts to reach as many Americans as possible.”
Wegovy® (semaglutide) injection 2.4 mg for weight administration since 2021.4 Wegovy® pill provides a magnitude of weight loss that no other oral GLP-1 obesity candidate has been capable to duplicate in phase 3 trials, boastful an average weight loss of around 17% (16.6%), when utilized along with a deficit calorie diet and exercise and if all patients remained on treatment, compared to around 3% (2.7%) for placebo.
23 January 2026
23 January 2026
23 January 2026
23 January 2026